<DOC>
	<DOC>NCT01421940</DOC>
	<brief_summary>Sexual dysfunctions are well-recognized complications after rectal cancer surgery. Damage to the pelvic plexus and pelvic splanchnic nerves results in ejaculatory dysfunction. The purpose of this study is to evaluate the efficacy of Udenafil(Zydena®, Dong-A Pharmaceutical co., Ltd, Seoul, Korea) in penile rehabilitation for patients who undertake total mesorectal excision.</brief_summary>
	<brief_title>The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Age : 2065 Rectal cancer within 15cm from anal verge Patients with more than 5 points decreased IIEF5 after operation Patients with sexual activity Preoperative IIEF5 : ≤14 Recent MI, CVA, nitrate medication Severe cardiovascular disease, psychiatric disease Severe hepatic dysfunction (GOT, GPT ≥100IU/L) Renal dysfunction (Cr ≥2mg/dl)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Udenafil</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>penile rehabilitation</keyword>
	<keyword>total mesorectal excision</keyword>
</DOC>